Loading
Kairos Pharma, Ltd. Stock: price and insider trades · United States
US·Mcap US$8.3M
No insider purchase over the last 90 days. The latest was filed 25 Nov 2024.
Kairos Pharma, Ltd.: what insiders have been doing
This page follows insider dealings at Kairos Pharma, Ltd. as filed with SEC (Form 4). The last twelve months, up to 18 October 2026, brought 8 filings signed by 7 insiders.
The filings describe grants, exercises and other transfers rather than trades on the open market. Grants and option exercises follow pay plans set in advance, so they reveal less about an insider's own view than a purchase made with personal money.
With 8 filings in twelve months, the company is quieter than the median of 19 filings across the 5,808 companies we follow on the same exchange. Since 2024, the database holds 3 purchases and no sales by insiders of the company.
No insider has bought Kairos Pharma, Ltd. shares on the open market in the past twelve months. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 60 days. For comparison, the SEC allows two business days to file a Form 4.
Other companies in the same market with recent insider buying flagged by our signals: GameStop Corp. and Heico Corp. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
14
Thresholds
n/a
Buy Volume
€9,315
3 ops. · all time
Sell Volume
n/a
n/a
Who traded when
BuySaleDoug Samuelson1 buy
John S. Yu1 buy
Ramachandran Murali1 buy
Analyst consensus: bullish or bearish?
Analysts rate Kairos Pharma, Ltd. Strong Buy (bullish), based on 2 analysts. Average price target: US$7.00.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$0.39
Analyst consensus
2 analystsStrong buy
US$2.00Target US$7.00(+1713%)US$12.00
Income statement
EBITDA-US$5.3M
Net income-US$5.4M0.0% margin
Valuation
PER (forward)-0.6x
P/Book1.6x
Balance sheet & cash
Market capUS$8.3M
Total debtUS$638k
Free Cash Flow-US$3.4M
Profitability & ownership
ROE-93.8%
ROA-54.8%
% insiders37.2%
% institutions6.9%
Last declaration on 30 December 2025
Declarations14 total
171,756 shares0COMMON STOCKSEC:0001493152-25-029601:0
10,000 shares0COMMON STOCKSEC:0001493152-25-028895:0
19,084 shares0COMMON STOCKSEC:0001493152-25-028895:1
152,672 shares0COMMON STOCKSEC:0001493152-25-025224:0
152,672 shares0COMMON STOCKSEC:0001493152-25-025198:0
190,840 shares0COMMON STOCKSEC:0001493152-25-025197:0
10,000 shares0COMMON STOCKSEC:0001493152-25-025205:0
19,084 shares0COMMON STOCKSEC:0001493152-25-025203:0
14,000 shares0COMMON STOCKSEC:0001641172-25-002927:0
14,000 shares0COMMON STOCKSEC:0001493152-25-008105:0
14,000 shares0COMMON STOCKSEC:0001493152-25-008106:0
200 shares@ US$1.59100.0% of flowCOMMON STOCKSEC:0001493152-24-047695:0
Canonical exit: 23 Feb 2025 (T+90)
2,500 shares@ US$1.50100.0% of flowCOMMON STOCKSEC:0001493152-24-047526:0
Canonical exit: 20 Feb 2025 (T+90)
4,000 shares@ US$1.44100.0% of flowCOMMON STOCKSEC:0001493152-24-047261:0
Canonical exit: 18 Feb 2025 (T+90)
14 of 14 declarations
About Kairos Pharma, Ltd.
Kairos Pharma, Ltd. is a pharmaceutical company listed on the XNAS market, specializing in the development of innovative treatments. It focuses on the research and commercialization of therapeutic solutions for various diseases.
Recent ranked signals on the same market
Purchases our model currently ranks for the recommendations list.
All recommendations
